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Abstract
Introduction: It has been proposed that individual genetic variation contributes to the course of severe infections and 
sepsis. Recent studies of single nucleotide polymorphisms (SNPs) within the endotoxin receptor and its signaling 
system showed an association with the risk of disease development. This study aims to examine the response 
associated with genetic variations of TLR4, the receptor for bacterial LPS, and a central intracellular signal transducer 
(TIRAP/Mal) on cytokine release and for susceptibility and course of severe hospital acquired infections in distinct 
patient populations.
Methods: Three intensive care units in tertiary care university hospitals in Greece and Germany participated. 375 and 
415 postoperative patients and 159 patients with ventilator associated pneumonia (VAP) were included. TLR4 and 
TIRAP/Mal polymorphisms in 375 general surgical patients were associated with risk of infection, clinical course and 
outcome. In two prospective studies, 415 patients following cardiac surgery and 159 patients with newly diagnosed 
VAP predominantly caused by Gram-negative bacteria were studied for cytokine levels in-vivo and after ex-vivo 
monocyte stimulation and clinical course.
Results: Patients simultaneously carrying polymorphisms in TIRAP/Mal and TLR4 and patients homozygous for the 
TIRAP/Mal SNP had a significantly higher risk of severe infections after surgery (odds ratio (OR) 5.5; confidence interval 
(CI): 1.34 - 22.64; P = 0.02 and OR: 7.3; CI: 1.89 - 28.50; P < 0.01 respectively). Additionally we found significantly lower 
circulating cytokine levels in double-mutant individuals with ventilator associated pneumonia and reduced cytokine 
production in an ex-vivo monocyte stimulation assay, but this difference was not apparent in TIRAP/Mal-homozygous 
patients. In cardiac surgery patients without infection, the cytokine release profiles were not changed when comparing 
different genotypes.
Conclusions: Carriers of mutations in sequential components of the TLR signaling system may have an increased risk 
for severe infections. Patients with this genotype showed a decrease in cytokine release when infected which was not 
apparent in patients with sterile inflammation following cardiac surgery.
Introduction
Patients treated in ICUs following surgery or who are on
ventilation support are prone to nosocomial infections
[1,2]. The sequence of events leading to septic shock has
been connected to the presence of biochemical products
such as bacterial endotoxin or cytokines [3,4]. The innate
immune system recognizes conserved microbial struc-
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tures also termed pathogen-associated molecular pat-
terns (PAMPs) by pattern recognition receptors (PRRs)
[5]. Also, intrinsic mediators (danger/damage-associated
molecular patterns (DAMPs)) can induce an inflamma-
tory response involving similar host molecules [6].
Genetic variation of the pathogen recognition system is
thought to explain, at least in part, individual differences
in the reaction of patients to similar infectious stimuli. An
influence of single nucleotide polymorphisms (SNPs) of
pathogen recognition on susceptibility for infections and
sepsis has therefore been suggested [7]. Toll-like recep-
tors (TLRs) are one class of PRRs that sense bacterial,
viral or fungal molecular structures or nucleic acids and
i n d u c e  s y s t e m i c  i n f l a m m a t i o n  [ 8 ] .  T L R 4  r e c o g n i z e s
lipopolysaccharide (LPS) of Gram-negative bacteria as
well as intrinsic mediators such as high-mobility group
box-1 (HMGB-1) or heat-shock proteins [9]. TLR-signal-
ing involves at least four intracellular signaling adaptor
molecules termed myeloid differentiation response factor
88 (MyD88), toll/interleukin-1 receptor (TIR)-associated
protein (TIRAP), also known as MyD88-adaptor-like
(Mal), toll-receptor-associated molecule (Tram) and toll-
receptor-associated activator of interferon (Trif). TIRAP/
Mal acts as a bridging adaptor recruiting MyD88 to TLR2
or TLR4 [10].
For TLR4, which is encoded on chromosome 9, several
SNPs have been described, with the most frequent one
being the Asp299Gly/Thr399Ile variation. There have
been conflicting reports on the influence of this SNP on
severity of infections or outcome in prospective trials
[11].
Two SNPs within the gene coding for the intracellular
signal transducer TIRAP/Mal  (positioned on chromo-
some 11) have been recently described: one synonymous
SNP (rs7932766) was shown to be associated with menin-
geal tuberculosis in Vietnamese patients [12]. Another
TIRAP/Mal SNP (rs8177374) leading to an amino acid
exchange (Ser180Leu) has been shown to protect from
pneumococcal pneumonia when present in a heterozy-
gous state [13]. The frequencies of both genetic variations
in  TLR4  and  TIRAP/Mal  have been recently studied
worldwide in a comparative fashion, and it has been pro-
posed that differences between regional populations can
be attributed to selective pressure due to differences in
sepsis susceptibility [14,15].
A direct cause and effect relation between cytokine
release and carriage of SNPs of molecules implicated in
response to stimulation with LPS is not easy to discern as
a variety of factors such as the time of blood sampling and
the intensity of the infectious stimulus may strongly
influence the results. However, we attempted to perform
an association between mortality in patients with sequen-
tial polymorphisms of the LPS receptor complex (TLR4-
SNPs Asp299Gly/Thr399Ile and the TIRAP/Mal-SNP
Ser180Leu) or patients homozygous for the TIRAP/Mal
SNP in an observational retrospective cohort study of 375
patients. More precisely, we analyzed these genetic varia-
tions in different patient populations representing a large
proportion of patients in ICUs for their ability to mount
an adequate cytokine response, and furthermore investi-
gated a potential influence for risk of and course of septic
complications.
To further confirm our results in a group of 159
patients with ventilator associated pneumonia (VAP) we
related clinical and cytokine data to the genotype. Addi-
tionally, in these patients monocytes were stimulated
with LPS and cytokine release was correlated to the dif-
f e r e n t  g e n o t y p e s .  F i n a l l y ,  o u t  o f  a  t h i r d  g r o u p  o f  4 1 5
patients following cardiac surgery matched pairs were
used to determine whether non-infectious inflammatory
signals would be influenced by the different genotypes.
Materials and methods
Patient inclusion and data collection
The studies were all approved by the local ethics commit-
tees of the respective institutions and DNA testing was
permitted by either a signed broad written consent
including DNA testing before surgery (Group I and
Group III) or written informed consent provided by first-
degree relatives in the case of patients with VAP (Group
II). All steps were performed in accordance with the Hel-
sinki declaration. Statistical analysis was carried out after
anonymization of the patient's data. For all cohorts defi-
nition of sepsis (systemic inflammatory response syn-
drome (SIRS), sepsis, severe sepsis and septic shock) was
based on published criteria [16]. In brief: sepsis was
defined as the presence of criteria for SIRS in response to
a documented or clinically suspected acute infection.
Severe sepsis was defined as sepsis associated with either
evidence of hypoperfusion with organ dysfunction or
sepsis-induced hypotension. Septic shock was defined as
sepsis with sepsis-induced hypotension requiring vaso-
pressor therapy despite adequate fluid challenge along
with the presence of hypoperfusion and organ dysfunc-
tion.
Patients in the first group (Group I) were all treated in
the ICU of the Robert-Rössle-Klinik of the Charité-Uni-
versity Medical Center, Berlin, Germany between 1999
and 2004. Main inclusion criteria were a length of stay
(LOS) of more than the mean LOS in the ICU (6.4 days)
or death at any time following surgery. Both criteria were
considered indicative of a complicated course. Medical
records of these patients were examined for the develop-
ment of infectious complications and accompanying
medical conditions. Patients with end-stage tumor dis-
ease and chronic immunosuppression were excluded
from the analysis. Out of 601 eligible patients, 375 ful-
filled the inclusion criteria. Infections were defined asKumpf et al. Critical Care 2010, 14:R103
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described by the National Institutes of Health clinical
classification for nosocomial infections. Patients were fol-
lowed up until discharge from the hospital. Prior to sur-
gery, sampled blood or tissue specimens were examined
for common TLR4 and TIRAP/Mal SNPs. The frequency
of the TIRAP/Mal SNP in a subgroup of these patients
has been reported recently [17].
Additionally two prospective studies including 159
patients with VAP (Group II) and 415 patients following
cardiac surgery (Group III) were conducted. Patients in
Group II were observed over the period of 2004 to 2006
in Athens, Greece. Clinical and serum cytokine data from
a subgroup of 56 patients out of this cohort were included
in previous studies and have been published elsewhere
[18-20]. Patients were either hospitalized in the Depart-
ment of Critical Care of the Evangelismos' General Hos-
pital or in the second Department of Critical Care of the
ATTIKON University Hospital of Athens, Greece. All
patients were over 18 years of age and intubated for at
least 48 hours before diagnosis of sepsis. Inclusion crite-
ria were the concomitant presence of VAP, and sepsis,
severe sepsis or septic shock. VAP was diagnosed if all of
the following signs were present: a) core temperature
above 38°C or below 36°C; b) new or persistent consolida-
tion in lung X-ray; c) purulent trancheobronchial secre-
tions; and clinical pulmonary infection score above six, as
proposed elsewhere [1]. Exclusion criteria were the pres-
ence of a) neutropenia (< 500 neutrophils per mm3), b)
HIV infection, and c) intake of corticoids (> 1 mg/kg of
p r e d n i s o n e  o r  e q u i v a l e n t  f o r  m o r e  t h a n  o n e  m o n t h ) .
Enrolled patients were followed-up for 28 days. For these
patients the frequency of SNPs of TLR4 and TIRAP/Mal
have already been reported [15].
Patients in Group III were part of a prospective cohort
study determining the effect of genetic variations in
innate immunity receptors on the cortisol response post-
operatively . They were observed following elective car -
diac surgery over the period 2005 to 2006 in the
University Medical Center, Düsseldorf, Germany. Follow-
ing written informed consent patients underwent cardiac
or major vascular surgery, that is coronary artery bypass
surgery, valve surgery or combined procedures employ-
ing extracorporal circulation. Exclusion criteria consisted
of chronic corticosteroid medication and known disease
in the hypothalamic-pituitary-adrenal-axis. Blood sam-
ples were obtained at five different time points: on the
day of surgery between 07:00 and 09:00 am (0 hours) and
on ICU admission (4 to 6 hours) and on the 1st to 3rd
days following the procedure between 07:00 and 09:00
hours (24, 48 and 72 hours, respectively). We used a
matched-control approach to reduce confounding factors
of cytokine response. For each of the affected individuals,
one patient from the wild type (WT)-group and the TLR4
group was chosen as a control. Therefore post-surgical
cytokine levels were compared between patients with
double mutations (n = 13) and patients with Mal-
homozygous genotype (n = 5). A combination of 18
matched wild type patients and 18 TLR4 patients were
chosen as controls resulting in a subgroup of 54 analyzed
individuals. An additional group of 176 healthy blood
donors with known age and gender who consented to
anonymous genotyping served as controls for genotype
frequency.
DNA analysis
Tissue specimen and blood sampled earlier were exam-
ined with a previously described method [21]. TLR4
genotyping (rs4986790 for Asp299Gly, rs4986791 for
Thr399Ile) was performed by restriction fraction length
polymorphism- or melting curve analysis as described
elsewhere [21,22]. Genotyping for TIRAP/Mal
(rs8177374 for Ser180Leu) was achieved by melting curve
analyses employing the Lightcycler 2.0 (Roche Diagnos-
tics, Mannheim, Germany) using the following primers
and probes: sense primer: GCCAGGCACTGAGCAG-
TAGT, antisense primer: GTGGGTAGGCAGCTCT-
TCTG, anchor probe; Red640-GATGGTGCAGCCC
TCGGCCCC, sensor probe: AGGCCCAACAG
CAGGG-FL. The melting peaks are at 53°C and 62°C for
the wild type and mutated sequences, respectively. Due to
secondary structures and allele biased amplification
within the region of this SNP, analysis of heterozygous
genotypes may sometimes result in false homozygous
results. Therefore, all mutated samples were reanalysed
by conventional restriction fraction length polymorphism
as described in [13].
Monocyte isolation and ex-vivo stimulation
Peripheral blood mononuclear cells were isolated after
gradient centrifugation of heparinized whole blood over
Ficoll Hypaque (Biochrom, Berlin, Germany) and three
consecutive washings with PBS (pH 7.2) (Merck, Darm-
stadt, Germany); after flask incubation purity of adherent
CD14-positive cells was more than 95%. Cells were stim-
ulated with 1 ng/ml of purified endotoxin (LPS) from
Escherichia coli O155:B5 (Sigma Co, St. Louis, MO,
USA). TNF-α, IL-6 and IL-10 were estimated in superna-
tants [18].
Measurement of cytokines
A 5 ml sample of blood was collected in a sterile and
pyrogen-free tube. After centrifugation, serum was kept
at -70°C until assayed. In Group II concentrations of
TNF-α, IL-6 and IL-8 in serum, and of TNF-α, IL-6 and
IL-10 in supernatants were estimated in duplicate by an
ELISA (Diaclone, Paris, France). Lower detection limits
were 3.12 pg/ml for TNF-α, 6.25 pg/ml for IL-6, 62.50 pg/
ml for IL-8, and 12.50 pg/ml for IL-10. Concentrations ofKumpf et al. Critical Care 2010, 14:R103
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cytokines in supernatants were expressed as pg/104 cells.
Cytokine analysis in patients of Group III was performed
with the Cytokine Ten-Plex antibody bead kit (Biosource
Europe, Nivelles, Belgium) on a Luminex xMAP system
(Luminex, Austin, TX, USA) (Sensitivity for the assays:
interferon (IFN)-γ: 5 pg/ml, IL-1b: 15 pg/ml, IL-2: 6 pg/
ml, IL-4: 5 pg/ml, IL-5: 3 pg/ml, IL-6: 3 pg/ml, IL-8: 3 pg/
ml, IL-10: 5 pg/ml, TNF-α : 10 pg/ml and granulocyte
macrophage colony-stimulating factor: 15 pg/ml respec-
tively). Data on cytokine values other than those pre-
sented in the current study are currently being analyzed
for subsequent publication and are therefore not all
included in this study.
Statistical analysis
Differences in categorical data between patient groups
were analyzed with the chi-squared test and with Fisher's
exact two-tailed test for expected frequencies of less than
five. Numerical data were expressed as means ± standard
deviation (SD) if they followed a normal distribution or
medians and interquartile range or median and 95% con-
fidence intervals (CI) for non-normal distribution. For
comparisons between groups the Kruskall-Wallis test, the
Mann-Whitney U test or one-way analysis of variance
with a Bonferroni correction and within a group the Wil-
coxon's rank sum test were used, respectively. Odds ratios
(OR) were determined by Mantel and Haenzel's statistics.
For calculation, the SPSS for Windows software, release
14.0 (SPSS Inc., Chicago, IL, USA) and the Prism 5.01 for
Windows (GraphPad Software, San Diego, CA, USA)
software were used. A two-tailed P < 0.05 was considered
significant.
Results
Frequency of TIRAP/Mal and TLR4 polymorphisms
In all patients examined (n = 949), 252 carried the
TIRAP/Mal  SNP with 229 being heterozygous and 23
homozygous for this allele. The resulting allele frequency
was 0.145, which is consistent with other reports and our
own control group consisting of 176 healthy individuals
from Germany (Table 1). In all patient cohorts, this SNP
was in Hardy-Weinberg Equilibrium. Of 127 individuals
with TLR4 variants two patients displayed the Thr399Ile
allele only, and three displayed only the Asp299Gly allele.
As recently described for European populations in all
other patients, the Asp299Gly and Thr399Ile SNPs were
cosegregating [15]. Three patients were homozygous for
both alleles. The allele frequency for any TLR4 SNP was
0.069, which is in line with previous studies [11].
Overall, 30 individuals had a combination of TIRAP/
Mal and TLR4 SNPs. One patient was TLR4 homozygous
and TIRAP/Mal heterozygous. Of 29 TLR4 heterozygous
mutation carriers, 24 were TIRAP/Mal heterozygous and
5 homozygous. The distribution of SNPs in the studied
patients and the cohort of healthy controls is shown in
detail in Table 1.
Clinical influence of genotypes on postoperative infection 
severity in surgical patients
The 375 patients enrolled in the first cohort of patients
(Group I) were unrelated European Caucasians. The
mean age of patients was 61.8 years (SD: ± 12.6) and 137
(36.5%) patients were female. Overall, 203 patients in
Group I developed infections. No association with single
genotypes and susceptibility for infection or specific
microorganisms was found. For risk associations with
severe sepsis we compared the SNP carriers (41 heterozy-
gous TLR4, and 10 homozygous and 75 heterozygous car-
riers of the TIRAP/Mal-SNP) with WT-patients (n =
240). In our analysis, the TIRAP/Mal homozygous geno-
type influenced patient morbidity resulting in higher risk
of severe infections (OR: 7.3; 95% CI: 1.89 to 28.50; P <
0.01). Furthermore, in nine patients the combination of
TLR4 and TIRAP/Mal SNPs significantly contributed to
the risk of severe infections as shown in Table 2 (OR 5.5;
95% CI: 1.34 to 22.64; P = 0.02). This effect was not influ-
enced by the type of infection in these two genotype
groups. However, an influence of infection type was
observed in the remaining subgroups (TLR4, TIRAP/Mal
heterozygous and wild type-patients). In these patients
presence of pneumonia and peritonitis contributed to the
risk of severe infections. A detailed summary of this
patient cohort is presented in the supplementary material
in Tables S1, S2 and S3 in Additional file 1.
Cytokine release and monocyte stimulation in patients 
with ventilator-associated pneumonia
To further study the apparent impact of these double
mutations on patients in ICUs we examined 159 Cauca-
sian patients of Greek ethnicity (Group II) as part of a
prospective cohort study. All these patients were on ven-
tilator support as part of the treatment for brain hemor-
rhage, multiple injuries, primary respiratory failure or
postoperative support, and developed VAP predomi-
nately caused by Gram-negative bacteria during their
treatment. Mean age of patients was 59.6 years (SD: ±
18.6). Forty (25%) patients were female. Patient character-
istics were similarly distributed over the genotype groups
as shown in Tables S1, S2 and S4 in Additional file 1. Of
the patients, 106 were carriers of only WT alleles; 9 were
carriers of only TLR4 SNP alleles; 41 were carriers of at
least one TIRAP/Mal SNP allele; and 3 were carriers of
both  TLR4  and  TIRAP/Mal  SNP alleles. Septic shock
occurred among 47 (44.3%), 6 (66.7%), 19 (46.3%), and
none of them, respectively.
When comparing circulating cytokine levels and their
correlation to the TLR4 and TIRAP/Mal genotype, indi-
viduals with combined mutations in TLR4 and TIRAP/Kumpf et al. Critical Care 2010, 14:R103
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Mal had very low circulating cytokine levels of IL-6 (WT-
patients vs. TIRAP/Mal +TLR4, P = 0.01 for IL-6) and IL-
8, while all other individuals, including those with single
mutations in either TLR4 or  TIRAP/Mal  had elevated
cytokine levels at day 1 after diagnosis of pneumonia. Fig-
ure 1 shows cytokine values in patients of Group II on day
1 after diagnosis of VAP.
To investigate the influence of different genotypes on
the cytokine induction pattern, monocytes from these
patients were isolated and stimulated ex-vivo with LPS.
Concentrations of TNF-α and IL-6 in cell supernatants of
patients bearing the wild-type phenotype and of carriers
of  TIRAP/Mal  or  TLR4  polymorphisms showed an
increase of cytokine levels. Individuals with a double
Table 1: Distribution of genotypes in the patients and healthy controls
Genotype TIRAP/Mal
Wild type heterozygous Homozygous
Group I
(n = 375)
Wild type 240 (64.0%) 75 (20.0%) 10 (2.7%) AF TIRAP/Mal:
0.140
TLR4 heterozygous 41 (10.9%) 7 (1.9%) 1 (0.3%)
homozygous -- 1 (0.3%) --
AF TLR4:
0.068
Wild type heterozygous Homozygous
Group II
(n = 159)
Wild type 106 (66.7%) 40 (25.2) 1 (0.6 %) AF TIRAP/Mal:
0.142
TLR4 heterozygous 9 (5.7%) 3 (1.9%) --
homozygous -- -- --
AF TLR4:
0.038
Wild type heterozygous Homozygous
Group III
(n = 415)
Wild type 254 (61.2%) 89 (21.4%) 7 (1.7%) AF TIRAP/Mal:
0.151
TLR4 heterozygous 45 (10.8%) 14 (3.4%) 4 (1.0%)
homozygous 2 (0.5%) -- --
AF TLR4:
0.080
Wild type heterozygous Homozygous
Controls 
(n = 176)
Wild type 122 (69.3%) 26 (14.8%) 2 (1.1%) AF TIRAP/Mal:
0.102
TLR4 heterozygous 20 (11.4%) 3 (1.7%) 1 (0.6%)
homozygous 1 (0.6%) 1 (0.6%) --
AF TLR4:
0.080
Allele frequencies equal between the groups. All groups in Hardy-Weinberg-Equilibrium: For TLR4: Group 1: P = 0.55; Group II: P = 0.62; Group III: 
P = 0.64; Controls: P = 0.36. For TIRAP/Mal: Group 1: P = 0.12; Group II: P = 0.40; Group III: P = 0.54; Controls: P = 0.34.
AF, allelic frequency, Mal, MyD88-adaptor-like, MyD88, myeloid differentiation response factor 88, TIR, toll/interleukin-1 receptor, TIRAP, TIR-
associated protein, TLR, toll-like receptor.Kumpf et al. Critical Care 2010, 14:R103
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mutation in TLR4 and TIRAP/Mal, however, exhibited a
lack of inducibility for TNF-α and IL-6 on day 1 after
diagnosis (Figure 2). Patients carrying no mutations or
either TLR4 or TIRAP/Mal mutations showed a stronger
induction of IL-6 following LPS-stimulation compared
with patients with double mutations, although the differ-
ence did not reach statistical significance. Similar results
were seen for TNF-α although less pronounced. No dif-
ferences in cytokine concentrations of monocyte super-
natants between patients bearing the wild-type and
carriers of polymorphisms were found on day 7 (data not
shown).
Influence of genotypes on cytokine release following 
cardiac surgery
A third group of patients was then examined to distin-
guish between a predominately sterile inflammatory
stimulation as compared with the stimulus towards
immune cells by bacterial ligands. The patients studied
following cardiac surgery were all of Caucasian descent.
Patient characteristics of this cohort and the matched
patients are shown in Tables S1, S2 and S5 in Additional
file 1. There were no statistically significant differences in
the cytokine levels following surgery over the study
period between the subgroups (Figure 3). The postopera-
tive course was not related to cytokine levels in these
patients (data not shown). Interestingly, patients receiv-
ing cardiac surgery exhibited markedly higher levels of
IL-6 following the procedure in all studied genotypes as
compared with patients suffering from infection approxi-
mately 24 hours following the insult. Although the results
were obtained by different cytokine-detection assays
there seem to be different mechanisms responsible for
the release of cytokines in operated patients.
Discussion
Patients suffering from infections seem to react individu-
ally to a similar insult. This capability to combat an infec-
tion is thought to be at least in part influenced by genetic
factors [23]. Despite important advances in the under-
standing of the pathophysiological processes leading to
sepsis and septic shock [4,24,25], knowledge on the role
of genetic factors contributing to sepsis susceptibility has
not yet translated into improved outcome [26,27].
In the first part of this study we were able to show an
association between the risk of severe infections and a
combination of genetic variants in sequential molecules
of the LPS-sensor consisting of TLR4  and its adaptor
TIRAP/Mal. The presence of TLR4 mutations in combi-
nation with TIRAP/Mal variants - either homozygous or
heterozygous - resulted in a statistically significant
increase in the risk of severe infections. Despite the fact
that the number of patients carrying these mutations is
low, we found intriguingly low serum levels of pro-
inflammatory cytokines in double-mutant individuals in
a second cohort (Group II). Additionally we found that
monocytes of these patients show decreased cytokine
production upon stimulation with LPS. One might spec-
ulate that moderate defects in TLR4 and TIRAP/Mal
function may accumulate to induce significant alterations
of TLR4 dependent signals. However, clinical outcome
data in this cohort could not support the findings with
regard to sepsis severity. One reason for this discrepancy
could be that the second cohort consisted of more
severely ill patients already suffering from infections
caused by highly resistant Gram-negative pathogens.
Moreover, other confounding factors may influence those
effects such as preexisting conditions, type of infection in
surgical patients or causing microrganisms. As the innate
Table 2: Association between septic complications and genotype in 375 patients of Group I
Genotype Severe Infections (n = 102) aOR 95% CI P value
Wild-type
(n = 240)
64 (26.7%) 0.87 0.51 - 1.48 0.69
Mutant alleles
TLR4 (n = 41) 10 (24. 4%) 1.57 0.73 to 3.37 0.33
TIRAP (het)
(n = 75)
15 (20.0%) 0.87 0.49 to 1.56 0.65
TIRAP (hom) (n = 10) 7 (70.0%) 7.33 1.89 to 28.50 < 0.01
TIRAP/TLR4 genotype (n = 9) 6 (66.7%) 5.50 1.34 to 22.64 0.02
aOR (odds ratio) when comparing severe infections (severe sepsis and septic shock) to patients with no infection. Calculated by comparison of 
wild type-patients with patients bearing other variants through Mantel-Haenzel's statistic and Fisher's exact test.
CI, confidence interval, het, heterozygous, hom, homozygous, Mal, MyD88-adaptor-like, MyD88, myeloid differentiation response factor 88, OR, 
odds ratio, TIR, toll/interleukin-1 receptor, TIRAP, TIR-associated protein, TLR, toll-like receptor.Kumpf et al. Critical Care 2010, 14:R103
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immune response to bacterial infection has to be
mounted early and effectively, genetic influence on
cytokine response in infection may determine effective-
ness of bacterial killing [28].
Supporting our results, it has been recently found that
severe sepsis and septic shock is associated with
decreased expression of TLR4 on host immune cells [29].
Thus, a lack in TLR4 signaling may be associated with a
worse outcome of disease, which also correlates with the
recent findings suggesting that immunosuppression
caused by negative regulators of TLR signaling are associ-
ated with sepsis mortality [30].
To further differentiate whether the observed lack in
inducibility of cytokines depended on the type of inflam-
mation, either bacterial infection or sterile inflammatory
stimulus, we also assessed postoperative cytokine
response following cardiac surgery (Group III). This
strong inflammatory reaction is a consequence of isch-
emia-reperfusion injury and is observed frequently fol-
lowing procedures involving cardiopulmonary bypass
[31]. DAMPs are thought to be involved in this process
and previous studies have associated this phenomenon to
the innate immune system [32]. In this non-infectious
g r o u p ,  w e  w e r e  n o t  a b l e  t o  s h o w  a  d i f f e r e n c e  i n  t h e
cytokine response between the genotype groups. This
could be in part explained by the hypothesis that the
involvement of endogenous danger signals compared
with bacterial ligands involves further elements of the
innate immune system, or that TLR4 is not a main recep-
tor of DAMPs in this group of patients. This could poten-
tially explain the difference observed in cytokine
concentrations between patients following cardiac proce-
dures as compared with the patient group with pneumo-
nia.
TIRAP/Mal is an important adaptor molecule for intra-
cellular signaling of both TLR4 and TLR2 [10]. As one of
Figure 1 Impact of TIRAP/Mal or TLR4 polymorphisms or their combinations on circulating cytokine levels. Cytokine serum levels (pg/ml) were 
measured on day 1 after diagnosis of ventilator-associated pneumonia in Group II. Values are shown as median +/- 95% confidence interval (CI) and 
as mean +/- standard error. Number of patients in each group: Controls = 106, TIRAP/Mal (heterozygotes and homozygotes reported together) = 41, 
TIRAP/Mal-TLR4 = 3, TLR4 = 9. P values refer to significant differences compared with patients bearing the wild-type for all tested polymorphisms. Com-
parison calculated with Mann-U Whitney test. In this figure TIRAP/Mal is named TIRAP for readability.Kumpf et al. Critical Care 2010, 14:R103
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four adaptors for TLR4 signaling [33], TIRAP/Mal func-
tions as a 'bridging molecule' for MyD88 [34]. A recently
published study postulated a protective effect of the
heterozygous TIRAP/Mal variant (Ser180Leu) for pneu-
mococcal disease [13]. A study on patients with severe
forms of tuberculosis, the rate of meningeal manifesta-
tions was associated with a synonymous TIRAP/Mal
SNP, but not with the above mentioned variant [12]. Both
investigations found an altered cytokine release in cell-
stimulation assays, supporting the view that these SNPs
are functionally relevant. Therefore, a second important
finding of our study was the significantly increased risk
for severe infections in TIRAP/Mal-homozygous
patients. This supports previous findings of Khor and
colleagues [13]. Although we could not observe a signifi-
cant reduction in risk for TIRAP/Mal-heterozygous
patients compared with WT-patients as seen in the Khor
and colleagues study, comparison of homozygous and
heterozygous patients was statistically different. As only
one patient in Group II was TIRAP/Mal-homozygous, no
comparison of patients was possible here.
Activation of TLR4 may lead to a differential use of
intracellular adaptors depending on the ligand that is
bound to it [35]. Thus, a disturbance in the TLR4-TIRAP/
Mal axis could lead to a predominant activation of the
TIRAP/Mal-independent signaling pathway, which could
explain the reduced release of nucleur factor (NF)-kB-
dependent cytokines. Therefore, a potential 'shunting' of
signals via a second pathway (Trif/Tram) could result in
an unbalanced cytokine release brought about by inter-
feron regulatory factor 3 (IRF3) and the release of type I
interferon-α and -β [36]. It has recently been shown that
IRF3 is crucial for endotoxin tolerance and activation
may result in a reduction of cytokine release upon LPS-
stimulation [36]. It is not known whether this may lead to
a change in the clinical course of sepsis, but animal mod-
els showed an influence on sepsis mortality if IRF3 was
pharmacologically inhibited [37]. In contrast, in TIRAP/
Mal knock-out mice or in macrophages with nonfunc-
tional TIRAP/Mal, the cytokine release via NF-κB was
strongly reduced, while IRF3-dependent signals were
almost unaltered [33]. A clinical trial such as the one pre-
sented here can only yield associations of genetic varia-
tions and the observed findings. For proving a causal link
an animal model is needed with transgenic mice carrying
either the human gene(s) of interest or its mutated vari-
ant(s). Our interpretation that the decreased ability to
induce cytokines is a cause of an altered course of infec-
tious diseases at this point is pure speculation.
An interesting observation was the lack of differences
of cytokine stimulations between patients carrying WT
alleles and those carrying SNP alleles on day 7. The only
probable explanation may come from the known changes
of responsiveness of monocytes to ex vivo stimulation
during the course of sepsis, which could depend on other
factors such as secondary infections or the anti-inflam-
matory response. We were not able to associate these
mechanisms to clinical or cytokine data in our patients.
In addition, recently generated data in TLR2 and TLR4
knock-out mice give strong evidence that the TLR-path-
way plays a pivotal role in the stress-hormone axis after
LPS-challenge as well [38]. So the course of infections in
patients with the described SNPs is potentially linked to
an altered stress response and may therefore influence
severity of sepsis. However, data on the influence of
TIRAP/Mal variants on the stress-hormone axis are lack-
ing to date.
The TLR4 SNP Asp299Gly/Thr399Ile studied here was
found to cosegregate in 98% of the individuals in these
European populations, confirming previous data in the
Figure 2 Impact of TIRAP/Mal or TLR4 polymorphisms or their 
combinations on monocyte release of IL-6 and TNF-α following 
LPS-stimulation. Monocytes were isolated from patients on day 1 af-
ter diagnosis of ventilator-associated pneumonia. Cells were then 
stimulated in vitro with lipopolysaccharide (LPS) for 24 hours, and IL-6 
content was assessed by ELISA as described in the Materials and Meth-
ods section. Shown are mean values ± standard deviation. Patient 
numbers are as described in Figure 1. SE, standard error; WT, wild type.Kumpf et al. Critical Care 2010, 14:R103
http://ccforum.com/content/14/3/R103
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literature [11]. In the present study the 299/399 TLR4
haplotype, when present without TIRAP/Mal mutations,
was only weakly associated with susceptibility and course
of disease in both groups. Our results also failed to show
an association of the TLR4 299/399 haplotype with the
incidence or type of microorganisms in surgical infec-
tions. Small previous studies on the TLR4 Asp299Gly/
Thr399Ile haplotype showed higher disease susceptibility
and higher incidence of infections caused by Gram-nega-
tive microorganisms [39], but this was not supported by
subsequent studies [40,41]. The normal responses of indi-
viduals bearing this allele following LPS challenge in vitro
[42-44] and in vivo [45] support this lack of association.
Whether the presence of TLR4  haplotypes containing
only the Asp299Gly or Thr399Ile SNPs is associated with
Gram-negative infection susceptibility cannot be con-
cluded from our study, due to the small number of
patients carrying these haplotypes. However, in individu-
als bearing the Asp299Gly TLR4  haplotype alone an
altered cytokine response to LPS and increased suscepti-
bility for sepsis has been reported [15,46].
As mentioned above, both TLR4  and  TIRAP/Mal
genetic variants differ significantly in their frequency
according to geographic locations [14,15]. This suggests
that selective pressure has been present as a consequence
of different disease susceptibilities. In these studies differ-
ences in cytokine release according to the genetic varia-
tions have been proposed to be the key functional factor
supporting the results presented here.
Conclusions
Recognition of microbial products via TLRs and subse-
quent signaling is crucial for the innate immune system
to initiate a response. Genetic alterations affect this
response and are related to individual variations in the
course of sepsis. In summary, our studies describe a novel
association between common genetic polymorphisms in
sequential elements of the endotoxin recognition system
(TLR4  and the intracellular signaling adaptor TIRAP/
Mal) and the course of sepsis and pneumonia. However,
we were not able to show an effect on susceptibility to
infections. This could indicate that variant genes in the
innate immune receptor system apparently are not affect-
ing the capability to sense invading microorganisms, but
rather the appropriate initiation and modulation of the
innate immune response. These findings are supported
by the fact that following cardiac surgery a strong and
non-infectious stimulus does not lead to an altered
cytokine response when comparing the genotype groups.
Further clinical and experimental studies are necessary to
Figure 3 Time-dependent cytokine release in cardiac surgery patients. Timepoints were defined as: preoperative (0), immediately postoperative 
(4 to 6 hours), first postoperative day (24 hours), 2nd (48 hours) and 3rd postoperative day (72 hours). Samples were taken between 7:00 and 9:00 a.m. 
except postoperatively. Different genotype groups (DSNP = Mal/TLR4 combination, light grey bars; Mal[hom] = TIRAP/Mal-homozygous, grey bars; 
TLR4 = patients with TLR4-SNPs, dark grey bars; WT = wild-type patients, black bars). There were no statistical differences between the genotype 
groups at the timepoints. All values are shown as median and interquartile range.Kumpf et al. Critical Care 2010, 14:R103
http://ccforum.com/content/14/3/R103
Page 10 of 11
elucidate the role of combined genetic variations in com-
plex diseases such as sepsis.
Key messages
• Individuals carrying genetic variations in both, 
TLR4 and the TLR signal transducer TIRAP/Mal had 
a higher risk of developing severe infectious compli-
cations following surgery as shown in two large stud-
ies including a total of 790 patients.
• Individuals carrying these two genetic variations 
had significantly lower cytokine levels both, in serum 
and following ex-vivo monocyte stimulation.
• These differences were not observed in a non-infec-
tious patient cohort with post-surgical SIRS indicat-
ing the effects observed to be microorganism-driven.
• We conclude that the increased risk for developing 
septic complications of double SNP carriers may be 
caused by an impaired ability to react to pathogens 
with an inflammatory response.
• Genotyping for innate immune receptors may iden-
tify individuals with increased risk for septic compli-
cations who should be subject to intensified 
prophylactic measures.
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